Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24754223 | 0.79 | USP5 (0.50) | USP5SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL258690 | 0.76 | KDM4E (0.54) | USP5SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL857765 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2HPGDHSD17B10RAB9ANPC1 | |
| SCHEMBL13799935 | 0.75 | SMN1; SMN2 (0.76) | SMN1; SMN2KDM4EHPGDRAB9ANPC1 | |
| SCHEMBL11967789 | 0.75 | USP5 (0.52) | USP5SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL3636921 | 0.73 | RAB9A (0.57) | USP5SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL9953323 | 0.73 | RAB9A (0.76) | USP5SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL29377227 | 0.73 | RAB9A (0.76) | USP5SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL312165 | 0.72 | USP5 (1.00) | USP5SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL11111412 | 0.72 | SMN1; SMN2 (0.50) | USP5SMN1; SMN2KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401829-B1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX INC (US) | 2012-08-22 | — | — | EP | claimed |
| EP-1401829-A4 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX INC (US) | 2004-10-27 | — | — | EP | claimed |
| EP-1401829-A1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | Microbiotix, Inc. (US) | 2004-03-31 | — | — | EP | claimed |
| US-20030181719-A1 | Novel heterocyclic antibacterial compounds | MICROBIOTIX, INC. | 2003-09-25 | — | — | US | claimed |
| WO-2002102792-A1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX, INC. (US) | 2002-12-27 | — | — | WO | claimed |
| EP-1401829-B1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-1401829-A4 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX INC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6777420-B2 | A URACIL COMPOUNDS AS ENZYME INHIBITORS, INHIBIT BACTERIAL DNA POLYMERASE, TREATING BACTERIAL DISEASES | MICROBIOTIX, INC. | 2004-08-17 | — | — | US | disclosed |
| EP-1401829-A1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | Microbiotix, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030181719-A1 | Novel heterocyclic antibacterial compounds | MICROBIOTIX, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2002102792-A1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181719-A1 | Novel heterocyclic antibacterial compounds | TOP1, TOP2A, TOP2B | USP5 2476/4885SMN1; SMN2 4430/4885KDM4E 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.